Guided Therapeutics, Inc, formerly known as SpectRx, is a medical technology company developing medical devices for the early detection of disease that leads to cancer. The firm's products are based on patented biophotonic technology using light to detect disease at the cellular level and provide painless and immediate results at the time of the examination. A platform technology for the early detection of disease that leads to cancer, the company's primary product is LuViva® Advanced Cervical Scan - a non-invasive cervical cancer detection device that identifies cervical cancers and precancers by scanning the cervix with light, then analyzing the light reflected or emanating from the cervix. LuViva also has potential applications as a screening tool in the developing world to be used where the Pap test or HPV test are not widely available. Publicly traded on NASDAQ from 1997 before becoming SBIR-involved, the firm shifted to OTC in 2003
